施貴寶 BMY 深 滬
已收盤 11-14 16:00:00 美东时间
46.65
-1.980
-4.07%
華盛通- 最 高48.3675
- 今 開48.27
- 成交量 1977.93万股
- 最 低 46.12
- 昨 收 48.63
- 總市值 949.79亿
- 52周最高 61.47
- 市盈率 靜 --
- 換手率 0.97%
- 52周最低 42.34
- 委 比 29.14%
- 總股本 20.36亿
- 歷史最高 74.275
- 量 比 1.61
- 振 幅 4.62%
- 歷史最低 2.74
- 每 手 1
- 風險率 5.09%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.
11-15 04:17
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
11-14 00:10
期权扫描 | AMD大涨9%，多张Call单涨超600%；CTRA期权成交放量超230倍！Call单高达99%
AMD大涨9%，多张Call单涨超600%；CTRA期权成交放量超230倍！Call单高达99%；杰富瑞一看涨期权涨超150%
11-13 20:49
Bristol-Myers Squibb Completes €5 Billion Note Offering
Bristol-Myers Squibb ( ($BMY) ) has shared an update. On November 10, 2025, BMS...
11-11 05:39
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announ...
11-07 21:30
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine, a biotech company advancing gene editing therapies, announced progress in its Wilson’s Disease (WD) and Alpha-1 Antitrypsin Deficiency (AATD) programs. New preclinical data for PM577 in WD will be presented at AASLD, with IND/CTA filings expected in early 2026 and clinical data in 2027. PM647 was nominated as the AATD development candidate, targeting mid-2026 IND filings. The company strengthened its leadership with Matthew Hawryl...
11-07 12:00
生物科技股复苏：四大因素推动行业上涨
经过四年的低迷期，生物科技行业正在迎来复苏，多个因素推动其股价回升。从积极的药物试验结果到并购活动的增加，再到药品推出的成功和利率下降，生物科技股的前景正在改善。分析师认为，投资者仍有机会把握这个反弹的机会，特别是一些潜力股值得关注。
11-04 16:53
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Aquestive Therapeutics announced key leadership changes to support the FDA-approved launch of Anaphylm™ and expand its pipeline. Matthew Davis, M.D., joins as Chief Development Officer, Gary Slatko, M.D., M.B.A., becomes interim Chief Medical Officer, and Peter Boyd, M.B.A., is promoted to Chief People Officer. These strategic moves aim to accelerate product development and commercialization efforts, particularly for Anaphylm™, a first-of-its-kin...
11-04 12:00
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.
11-03 23:29
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
<p>DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer. In this role, he will oversee the global commercial strategy for the Viaskin Peanut patch and lead the BLA submissions for children aged 1-7 years in 2026. With over 30 years in the biopharmaceutical industry, Kevin brings significant experience in product strategy and launches. He previously worked at Bristol-Myers Squibb and was a consultant for DBV since 2017. The compa...
11-03 21:30
公司簡介
公司名稱
|
施贵宝
|
行業分類
|
制药
|
業務描述
|
百时美施贵宝是一家以“研发并提供创新药物，帮助患者战胜严重疾病”为使命的全球性生物制药公司。公司拥有约25000名员工。2016年，百时美施贵宝全球研发投入达近50亿美元，占全年产品净销售额的28%。
|
Fear Of An AI Bubble? This Sector Is Quietly Surging While Tech Sinks
While AI stocks slide, healthcare is soaring. XLV leads November gains, outperforming tech as investors rotate.
11-15 04:17
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Pfizer plans to sell its remaining BioNTech stake through a $508 million block trade, ending a profitable Covid-19 vaccine partnership.
11-14 00:10
期权扫描 | AMD大涨9%，多张Call单涨超600%；CTRA期权成交放量超230倍！Call单高达99%
AMD大涨9%，多张Call单涨超600%；CTRA期权成交放量超230倍！Call单高达99%；杰富瑞一看涨期权涨超150%
11-13 20:49
Bristol-Myers Squibb Completes €5 Billion Note Offering
Bristol-Myers Squibb ( ($BMY) ) has shared an update. On November 10, 2025, BMS...
11-11 05:39
FDA Approved DARZALEX Faspro® for Adult Patients with High-Risk Smoldering Multiple Myeloma
DARZALEX Faspro® is co-formulated with Halozyme's ENHANZE® drug delivery technology SAN DIEGO, Nov. 7, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announ...
11-07 21:30
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine, a biotech company advancing gene editing therapies, announced progress in its Wilson’s Disease (WD) and Alpha-1 Antitrypsin Deficiency (AATD) programs. New preclinical data for PM577 in WD will be presented at AASLD, with IND/CTA filings expected in early 2026 and clinical data in 2027. PM647 was nominated as the AATD development candidate, targeting mid-2026 IND filings. The company strengthened its leadership with Matthew Hawryl...
11-07 12:00
生物科技股复苏：四大因素推动行业上涨
经过四年的低迷期，生物科技行业正在迎来复苏，多个因素推动其股价回升。从积极的药物试验结果到并购活动的增加，再到药品推出的成功和利率下降，生物科技股的前景正在改善。分析师认为，投资者仍有机会把握这个反弹的机会，特别是一些潜力股值得关注。
11-04 16:53
Aquestive Therapeutics Announces Leadership Expansion to Support Growth
Aquestive Therapeutics announced key leadership changes to support the FDA-approved launch of Anaphylm™ and expand its pipeline. Matthew Davis, M.D., joins as Chief Development Officer, Gary Slatko, M.D., M.B.A., becomes interim Chief Medical Officer, and Peter Boyd, M.B.A., is promoted to Chief People Officer. These strategic moves aim to accelerate product development and commercialization efforts, particularly for Anaphylm™, a first-of-its-kin...
11-04 12:00
BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership
BioNTech reports a Q3 loss but boosts 2025 revenue forecast to €2.6–2.8 billion, driven by Bristol Myers collaboration and cost optimization.
11-03 23:29
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
<p>DBV Technologies has appointed Kevin Trapp as Chief Commercial Officer. In this role, he will oversee the global commercial strategy for the Viaskin Peanut patch and lead the BLA submissions for children aged 1-7 years in 2026. With over 30 years in the biopharmaceutical industry, Kevin brings significant experience in product strategy and launches. He previously worked at Bristol-Myers Squibb and was a consultant for DBV since 2017. The compa...
11-03 21:30
派息除權日
|
每股總股息
| 派息日期 |
2025-10-03
|
0.62
|
2025-11-03
|
2025-07-03
|
0.62
|
2025-08-01
|
2025-04-04
|
0.62
|
2025-05-01
|
2025-01-03
|
0.62
|
2025-02-03
|
2024-10-04
|
0.60
|
2024-11-01
|
2024-07-05
|
0.60
|
2024-08-01
|
2024-04-04
|
0.60
|
2024-05-01
|
2024-01-04
|
0.60
|
2024-02-01
|
2023-10-05
|
0.57
|
2023-11-01
|
2023-07-06
|
0.57
|
2023-08-01
|
2023-04-06
|
0.57
|
2023-05-01
|
2023-01-05
|
0.57
|
2023-02-01
|
2022-10-06
|
0.54
|
2022-11-01
|
2022-06-30
|
0.54
|
2022-08-01
|
2022-03-31
|
0.54
|
2022-05-02
|
2022-01-06
|
0.54
|
2022-02-01
|
2021-09-30
|
0.49
|
2021-11-01
|
2021-07-01
|
0.49
|
2021-08-02
|
2021-03-31
|
0.49
|
2021-05-03
|
2020-12-31
|
0.49
|
2021-02-01
|
2020-10-01
|
0.45
|
2020-11-02
|
2020-07-02
|
0.45
|
2020-08-03
|
2020-04-02
|
0.45
|
2020-05-01
|
2020-01-02
|
0.45
|
2020-02-03
|
2019-10-03
|
0.41
|
2019-11-01
|
2019-07-03
|
0.41
|
2019-08-01
|
2019-04-04
|
0.41
|
2019-05-01
|
2019-01-03
|
0.41
|
2019-02-01
|
2018-10-04
|
0.40
|
2018-11-01
|
2018-07-05
|
0.40
|
2018-08-01
|
2018-04-05
|
0.40
|
2018-05-01
|
2018-01-04
|
0.40
|
2018-02-01
|
2017-10-05
|
0.39
|
2017-11-01
|
2017-07-05
|
0.39
|
2017-08-01
|
2017-04-05
|
0.39
|
2017-05-01
|
2017-01-04
|
0.39
|
2017-02-01
|
2016-10-05
|
0.38
|
2016-11-01
|
2016-06-29
|
0.38
|
2016-08-01
|
2016-03-30
|
0.38
|
2016-05-02
|
2015-12-30
|
0.38
|
2016-02-01
|
2015-09-30
|
0.37
|
2015-11-02
|
2015-07-01
|
0.37
|
2015-08-03
|
2015-04-01
|
0.37
|
2015-05-01
|
2014-12-30
|
0.37
|
2015-02-02
|
2014-10-01
|
0.36
|
2014-11-03
|
2014-07-01
|
0.36
|
2014-08-01
|
2014-04-02
|
0.36
|
2014-05-01
|
2013-12-31
|
0.36
|
2014-02-03
|
2013-10-02
|
0.35
|
2013-11-01
|
2013-07-02
|
0.35
|
2013-08-01
|
2013-04-03
|
0.35
|
2013-05-01
|
2013-01-02
|
0.35
|
2013-02-01
|
2012-10-03
|
0.34
|
2012-11-01
|
2012-07-03
|
0.34
|
2012-08-01
|
2012-04-03
|
0.34
|
2012-05-01
|
2012-01-04
|
0.34
|
2012-02-01
|
2011-10-06
|
0.33
|
2011-11-01
|
2011-06-29
|
0.33
|
2011-08-01
|
2011-03-30
|
0.33
|
2011-05-02
|
2011-01-05
|
0.33
|
2011-02-01
|
2010-09-29
|
0.32
|
2010-11-01
|
2010-06-30
|
0.32
|
2010-08-02
|
2010-03-30
|
0.32
|
2010-05-03
|
2009-12-30
|
0.32
|
2010-02-01
|
2009-09-30
|
0.31
|
2009-11-02
|
2009-07-01
|
0.31
|
2009-08-03
|
2009-04-01
|
0.31
|
2009-05-01
|
2008-12-30
|
0.31
|
2009-02-02
|
2008-10-01
|
0.31
|
2008-11-03
|
2008-07-02
|
0.31
|
2008-08-01
|
2008-04-02
|
0.31
|
2008-05-01
|
2008-01-02
|
0.31
|
2008-02-01
|
2007-10-03
|
0.28
|
2007-11-01
|
2007-07-03
|
0.28
|
2007-08-01
|
2007-04-03
|
0.28
|
2007-05-01
|
2007-01-03
|
0.28
|
2007-02-01
|
2006-10-04
|
0.28
|
2006-11-01
|
2006-07-05
|
0.28
|
2006-08-01
|
2006-04-05
|
0.28
|
2006-05-01
|
2006-01-04
|
0.28
|
2006-02-01
|
2005-10-05
|
0.28
|
2005-11-01
|
2005-06-29
|
0.28
|
2005-08-01
|
2005-03-30
|
0.28
|
2005-05-02
|
2005-01-05
|
0.28
|
2005-02-01
|
2004-09-29
|
0.28
|
2004-11-01
|
2004-06-30
|
0.28
|
2004-08-02
|
2004-03-31
|
0.28
|
2004-05-03
|
2003-12-30
|
0.28
|
2004-02-02
|
2003-10-01
|
0.28
|
2003-11-03
|
2003-07-01
|
0.28
|
2003-08-01
|
2003-04-02
|
0.28
|
2003-05-01
|
2002-12-31
|
0.28
|
2003-02-01
|
2002-10-02
|
0.28
|
2002-11-01
|
2002-07-02
|
0.28
|
2002-08-01
|
2002-04-03
|
0.28
|
2002-05-01
|
2002-01-02
|
0.28
|
2002-02-01
|
2001-10-03
|
0.28
|
2001-11-01
|
2001-07-03
|
0.28
|
2001-08-01
|
2001-04-04
|
0.28
|
2001-05-01
|
2001-01-03
|
0.28
|
2001-02-01
|
2000-10-04
|
0.25
|
2000-11-01
|
2000-07-05
|
0.25
|
2000-08-01
|
2000-04-05
|
0.25
|
2000-05-01
|
2000-01-05
|
0.25
|
2000-02-01
|
1999-09-29
|
0.22
|
1999-11-01
|
1999-06-30
|
0.22
|
1999-08-01
|
1999-03-30
|
0.22
|
1999-05-01
|
1999-01-06
|
0.43
|
1999-02-01
|
1998-09-30
|
0.39
|
1998-11-01
|
1998-06-30
|
0.39
|
1998-08-01
|
1998-04-01
|
0.39
|
1998-05-01
|
1997-12-30
|
0.39
|
1998-02-01
|
1997-10-01
|
0.38
|
1997-11-01
|
1997-07-01
|
0.38
|
1997-08-01
|
1997-04-02
|
0.38
|
1997-05-01
|
1996-12-31
|
0.76
|
1997-02-01
|
1996-10-02
|
0.75
|
1996-11-01
|
1996-07-02
|
0.75
|
1996-08-01
|
1996-04-02
|
0.75
|
1996-05-01
|
1996-01-03
|
0.75
|
1996-02-01
|
1995-10-04
|
0.74
|
1995-11-01
|
1995-07-05
|
0.74
|
1995-08-01
|
1995-04-03
|
0.74
|
1995-05-01
|
1994-12-30
|
0.74
|
1995-02-01
|
1994-10-03
|
0.73
|
1994-11-01
|
1994-06-27
|
0.73
|
1994-08-01
|
1994-03-25
|
0.73
|
1994-05-01
|
1994-01-03
|
0.73
|
1994-02-01
|
1993-09-27
|
0.72
|
1993-11-01
|
1993-06-28
|
0.72
|
1993-08-01
|
1993-03-29
|
0.72
|
1993-05-01
|
1993-01-04
|
0.72
|
1993-02-01
|
1992-09-28
|
0.69
|
1992-11-01
|
1992-06-26
|
0.69
|
1992-08-01
|
1992-03-30
|
0.69
|
1992-05-01
|
1991-12-27
|
0.69
|
1992-02-01
|
1991-09-30
|
0.60
|
1991-11-01
|
1991-06-28
|
0.60
|
1991-08-01
|
1991-04-01
|
0.60
|
1991-05-01
|
1990-12-28
|
0.60
|
1991-02-01
|
1990-10-01
|
0.53
|
1990-11-01
|
1990-06-29
|
0.53
|
1990-08-01
|
1990-04-02
|
0.53
|
1990-05-01
|
1989-12-29
|
0.53
|
1990-02-01
|
1989-09-19
|
0.50
|
1989-11-01
|
1989-06-30
|
0.50
|
1989-08-01
|
1989-04-03
|
0.50
|
1989-05-01
|
1988-12-30
|
0.50
|
1989-02-01
|
1988-10-03
|
0.42
|
1988-11-01
|
1988-06-27
|
0.42
|
1988-08-01
|
1988-03-25
|
0.42
|
1988-05-01
|
1988-01-04
|
0.42
|
1988-02-01
|
1987-09-28
|
0.35
|
1987-11-01
|
1987-06-26
|
0.35
|
1987-08-01
|
1987-03-30
|
0.70
|
1987-05-01
|
1986-12-26
|
0.70
|
1987-02-01
|
1986-09-29
|
0.55
|
1986-11-01
|
1986-06-27
|
0.55
|
1986-08-01
|
1986-03-31
|
0.55
|
1986-05-01
|
1985-12-07
|
0.47
|
1986-02-01
|
1985-09-30
|
0.47
|
1985-11-01
|
1985-06-08
|
0.47
|
1985-08-01
|
1985-03-09
|
0.47
|
1985-05-01
|
1984-12-08
|
0.40
|
1985-02-01
|
1984-10-01
|
0.40
|
1984-11-01
|
1984-06-29
|
0.40
|
1984-08-01
|
1984-04-02
|
0.40
|
1984-05-01
|
1983-12-30
|
0.30
|
1984-02-01
|
1983-10-03
|
0.30
|
1983-11-01
|
1983-07-01
|
0.30
|
1983-08-01
|
1983-01-03
|
0.52
|
1983-02-01
|
1982-10-04
|
0.52
|
1982-11-01
|
1982-07-02
|
0.52
|
1982-08-01
|
1982-04-04
|
0.60
|
1982-05-01
|
1982-04-02
|
0.52
|
1982-05-01
|
1982-01-04
|
0.46
|
1982-02-01
|
1981-10-05
|
0.46
|
1981-11-01
|
1981-07-06
|
0.46
|
1981-08-01
|
1981-04-06
|
0.46
|
1981-05-01
|
1981-01-05
|
0.40
|
1981-02-01
|
1980-10-06
|
0.40
|
1980-11-01
|
1980-06-30
|
0.40
|
1980-08-01
|
1980-03-27
|
0.40
|
1980-05-01
|
1979-12-27
|
0.36
|
1980-01-31
|
1979-10-04
|
0.36
|
1979-10-31
|
1979-06-28
|
0.36
|
1979-07-31
|
1979-04-01
|
0.36
|
1979-04-30
|
1978-12-28
|
0.31
|
1979-01-31
|
1978-10-01
|
0.31
|
1978-10-31
|
1978-06-29
|
0.31
|
1978-07-31
|
1978-03-30
|
0.31
|
1978-04-30
|
1977-12-29
|
0.28
|
1978-01-31
|
1977-10-02
|
0.28
|
1977-10-31
|
1977-06-26
|
0.28
|
1977-07-31
|
